Researchers from University College London’s Institute of Ophthalmology and Moorfields Eye Hospital, in collaboration with Allergan, Inc., have published results evaluating the effect of a single treatment with dexamethasone intravitreal implant (DEX implant) on patient-reported visual functioning in noninfectious intermediate or posterior uveitis. The vision outcome study data, based on the Phase III multicenter masked, randomized, sham-controlled, parallel group trial of 0.70 and 0.35 mg DEX implant (compared with a sham procedure), showed that the treatment group had clinically significant improvements as early as week eight which were maintained out to week 26.